In their study, Rodriguez-Otero et al. also revealed that the choice of subsequent anti-myeloma treatment post-CAR T-cell therapy varied greatly, including dexamethasone, carfilzomib, other anti-BCMA agents (i.e., belantamab), and other novel therapeutics (i.e., feladilimab, an inducible T-cell co-stimulator) [7]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.